A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Subjects With Negative Symptoms of Schizophrenia
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2018
At a glance
- Drugs TAK 831 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 22 Nov 2018 Planned number of patients changed from 315 to 234.
- 31 Aug 2018 Biomarkers information updated
- 19 Jan 2018 Status changed from not yet recruiting to recruiting.